Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 3:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,320 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Lenvatinib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions
ONM-100
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas
Conditions
Esophageal Neoplasms, Cancer of Esophagus, Cancer of the Esophagus, Esophageal Cancer, Esophagus Cancer, Neoplasm, Esophageal, Esophagectomy, Abnormalities, Digestive System, Digestive System Abnormalities
Interventions
Mayo Clinic Upper Digestive Disease Survey on Paper, Upper Digestive Disease (UDD Monitor) App
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
Interventions
Specimen collection
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Oropharyngeal Neoplasms, Head and Neck Cancer
Interventions
Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Results available

A Study for Patients With Head and Neck Cancer

NCT00415194
Conditions
Head and Neck Neoplasms
Interventions
pemetrexed, cisplatin, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
15
States / cities
Orange, California • Orlando, Florida • St. Petersburg, Florida + 12 more
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-321
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more
Conditions
Head and Neck Cancer
Interventions
Fenretinide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions
TILT-123, Avelumab
Biological · Drug
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oral Cancer
Interventions
Deep UV-M and AI Cytology Triage
Device
Lead sponsor
Anh Le
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Taxotere (Docetaxel), Alimta (Pemetrexed)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Esophageal Neoplasms, Esophagectomy, Brain Metastases
Interventions
Esophagectomy for esophageal cancer
Procedure
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Interventions
EOS-448, pembrolizumab, inupadenant, Dostarlimab, SOC chemotherapies
Drug
Lead sponsor
iTeos Belgium SA
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Diego, California • Bergen, New Jersey
Conditions
Head and Neck Cancer
Interventions
autologous EBV specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
2
States / cities
Houston, Texas
Conditions
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Interventions
CJRB-101, Pembrolizumab injection
Drug
Lead sponsor
CJ Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Irvine, California • Pittsburgh, Pennsylvania
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)
Biological · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Conditions
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
Conditions
Esophageal Cancer, Cancer of the Esophagus
Interventions
Pembrolizumab, Brachytherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Head and Neck Cancer
Interventions
bevacizumab, cisplatin, conventional surgery, intensity-modulated radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Conditions
Gastrointestinal Cancer
Interventions
Capecitabine, Sacituzumab govetican
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Detroit, Michigan